

SCHWERPUNKT: MALIGNEN LYMPHOME UND MULTIPLES MYELOM

Aktuelles zur Diagnostik und Therapie des Multiplen Myeloms (S. 10–13)

H. Goldschmidt

1. <https://atlasgekid.de/CurrentVersion/atlas.html>
 2. Rajkumar SV et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. *Lancet Oncol* 2014; 15: e538–548
 3. Onkopedia Leitlinie 2018. <https://www.onkopedia.com/de/onkopedia/guidelines/multiples-myelom/@@guideline/html/index.html> (Letzter Zugriff: 10.01.2020)
 4. McCarthy PL et al. Lenalidomide Maintenance After Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma: A Meta-Analysis. *J Clin Oncol* 2017; 35: 3279–3289 5. Holstein SA, and McCarthy PL. Immunomodulatory Drugs in Multiple Myeloma: Mechanisms of Action and Clinical Experience. *Drugs* 2017; 77: 505–520 6. Scheid C et al. Bortezomib before and after autologous stem cell transplantation overcomes the negative prognostic impact of renal impairment in newly diagnosed multiple myeloma: a subgroup analysis from the HOVON-65/GMMG-HD4 trial. doi:10.3324/haematol.2013.087585
 7. Mai EK et al. Bortezomib-based induction therapy with high or low-dose dexamethasone in newly diagnosed, transplant-eligible multiple myeloma. *Leukemia* 2019 Jan; 33 (1): 258–261
 8. Durie B et al. Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial. doi:10.1016/S0140-6736(16)31594-X
 9. Leiba M et al. Bortezomib-cyclophosphamide-dexamethasone (VCD) versus bortezomib-thalidomide-dexamethasone (VTD) -based regimens as induction therapies in newly diagnosed transplant eligible patients with multiple myeloma: a meta-analysis. *Br J Haematol* 2014; 166: 702–710
 10. Goldschmidt H et al. Bortezomib before and after high-dose therapy in myeloma: long-term results from the phase III HOVON-65/GMMG-HD4 trial. *Leukemia* 2018 Feb; 32(2): 383–390
 11. Neben K et al. Administration of bortezomib before and after autologous stem cell transplantation improves outcome in multiple myeloma patients with deletion 17p. *Blood* 2012; 119: 940–948 12. Scheid C et al. Infusion of Daratumumab in Combination Therapies - Practical Information for The Outpatient Area. *Dtsch Med Wochenschr* 2018; 143: 1201–1206
 13. Mateos MV et al. Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trial. *Lancet* 2019. doi:10.1016/s0140-6736(19)32956-3
 14. Facon T et al. Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma. *N Engl J Med* 2019; 380: 2104–2115 15. Dhakal B et al. Autologous Transplantation for Newly Diagnosed Multiple Myeloma in the Era of Novel Agent Induction: A Systematic Review and Meta-analysis. *JAMA Oncol* 2018; 4: 343–350
 16. Cavo M et al. Double autologous stem cell transplantation significantly prolongs progression-free survival and overall survival in comparison with single autotransplantation in newly diagnosed multiple myeloma: an analysis of Phase 3 EMN02/HO95 Study. *Cochrane Library*: <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/281/CN-01453281/frame.html>
-

Diffuses großzelliges B-Zell-Lymphom – Diagnostik und Therapie 2020 (S.29–37)

S. Sommer, M. Trepel, R. Claus

1. Cartwright R et al. The rise in incidence of lymphomas in Europe 1985–1992. *Eur J Cancer*; 1999; 35(4): 627–33
2. Anderson JR, Armitage JO, Weisenburger DD. Epidemiology of the non-Hodgkin's lymphomas: distributions of the major subtypes differ by geographic locations. Non-Hodgkin's Lymphoma Classification Project. *Ann Oncol* 1998; 9(7): 717–20
3. Shenoy PJ et al. Racial differences in the presentation and outcomes of diffuse large B-cell lymphoma in the United States. *Cancer* 2011; 117(11): 2530–40
4. Little RF et al. HIV-associated non-Hodgkin lymphoma: incidence, presentation, and prognosis. *JAMA* 2001; 285(14): 1880–5
5. Vishnu P, Aboulafia DM. AIDS-Related Non-Hodgkin's Lymphoma in the Era of Highly Active Antiretroviral Therapy. *Adv Hematol* 2012; 2012: 485943. doi: 10.1155/2012/485943
6. Alizadeh AA et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. *Nature* 2000; 403(6769): 503–11
7. Lenz G et al. Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways. *Proc Natl Acad Sci U S A*. 2008; 105(36): 13520–5
8. Cheson BD et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. *J Clin Oncol* 2014; 32(27): 3059–68
9. Tilly H et al. Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol* 2012; 23 Suppl 7: vii78–vii82
10. Coiffier B et al. Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte. *Blood* 2010; 116(12): 2040–5
11. Coiffier B et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. *N Engl J Med* 2002; 346(4): 235–42
12. Habermann TM et al. Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. *J Clin Oncol* 2006; 24(19): 3121–7
13. Pfreundschuh M et al. Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60). *Lancet Oncol* 2008; 9(2): 105–16
14. Pfreundschuh M et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. *Lancet Oncol* 2006; 7(5): 379–91
15. Cunningham D et al. Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles. *Lancet* 2013; 381(9880): 1817–26
16. Stiff PJ et al. Autologous transplantation as consolidation for aggressive non-Hodgkin's lymphoma. *N Engl J Med* 2013; 369(18): 1681–90
17. Schmitz N et al. Conventional chemotherapy (CHOEP-14) with rituximab or high-dose chemotherapy (MegaCHOEP) with rituximab for young, high-risk patients with aggressive B-cell lymphoma: an open-label, randomised, phase 3 trial (DSHNHL 2002-1). *Lancet Oncol* 2012; 13(12): 12050-59
18. Fitoussi O et al. Survival impact of rituximab combined with ACVBP and upfront consolidation autotransplantation in high-risk diffuse large B-cell lymphoma for GELA. *Haematologica* 2011; 96(8): 1136–43
19. Poeschel V et al. Four versus six cycles of CHOP chemotherapy in combination with six applications of rituximab in patients with aggressive B-cell lymphoma with favourable prognosis (FLYER): a randomised, phase 3, non-inferiority trial. *Lancet* 2020; 394(10216): 2271–81

20. Peyrade F et al. Attenuated immunochemotherapy regimen (R-miniCHOP) in elderly patients older than 80 years with diffuse large B-cell lymphoma: a multicentre, single-arm, phase 2 trial. *Lancet Oncol* 2011; 12(5): 460–8
21. Held G et al. Impact of rituximab and radiotherapy on outcome of patients with aggressive B-cell lymphoma and skeletal involvement. *J Clin Oncol* 2013; 31(32): 4115–22
22. Pfreundschuh M et al. Radiotherapy (RT) to bulky (B) and extralymphatic (E) disease in combination with 6xR-CHOP-14 or R-CHOP-21 in young good-prognosis DLBCL patients: Results of the 2x2 randomized UNFOLDER trial of the DSHNHL/GLA. *J Clin Oncol* 2018; 36, no. 15_suppl: 7574–7574
23. Bittenbring JT et al. Vitamin D deficiency impairs rituximab-mediated cellular cytotoxicity and outcome of patients with diffuse large B-cell lymphoma treated with but not without rituximab. *J Clin Oncol* 2014; 32(29): 3242–8
24. Vellenga E et al. Rituximab improves the treatment results of DHAP-VIM-DHAP and ASCT in relapsed/progressive aggressive CD20+ NHL: a prospective randomized HOVON trial. *Blood* 2008; 111(2): 537–43
25. Glass B et al. Refractory or relapsed aggressive B-cell lymphoma failing (R)-CHOP: an analysis of patients treated on the RICOVER-60 trial. *Ann Oncol* 2017; 28(12): 3058–64
26. Borgerding A et al. Rituximab retherapy in patients with relapsed aggressive B cell and mantle cell lymphoma. *Ann Hematol* 2010; 89(3): 283–9
27. Kessinger A et al. High-dose therapy and autologous peripheral blood stem cell transplantation for patients with lymphoma. *Blood* 1989; 74(4): 1260–5
28. Vose JM et al. Comparison of high-dose therapy and autologous bone marrow transplantation for T-cell and B-cell non-Hodgkin's lymphomas. *Blood* 1990; 76(2): 424–31
29. Gulati S et al. Treatment of patients with relapsed and resistant non-Hodgkin's lymphoma using total body irradiation, etoposide, and cyclophosphamide and autologous bone marrow transplantation. *J Clin Oncol* 1992; 10(6): 936–41
30. Patti C et al. High-dose cyclophosphamide, etoposide and BCNU (CVB) with autologous stem cell rescue in malignant lymphomas. *Eur J Haematol* 1993; 51(1): 18–24
31. Philip T et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. *N Engl J Med* 1995; 333(23): 1540–5
32. Crump M et al. Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study. *Blood* 2017; 130(16): 1800–8
33. Van Den Neste E et al. Outcome of patients with relapsed diffuse large B-cell lymphoma who fail second-line salvage regimens in the International CORAL study. *Bone Marrow Transplant* 2016; 51(1): 51–7
34. Philip T et al. High-dose therapy and autologous bone marrow transplantation after failure of conventional chemotherapy in adults with intermediate-grade or high-grade non-Hodgkin's lymphoma. *N Engl J Med* 1987; 316(24): 1493–8
35. Saez R et al. Autologous bone marrow transplantation in adults with non-Hodgkin's lymphoma: a Southwest Oncology Group study. *Hematol Oncol* 1994; 12(2): 75–85
36. Josting A et al. Treatment of primary progressive Hodgkin's and aggressive non-Hodgkin's lymphoma: is there a chance for cure? *J Clin Oncol* 2000; 18(2): 332–9
37. Gisselbrecht C et al. R-ICE versus R-DHAP in relapsed patients with CD20 diffuse large B-cell lymphoma (DLBCL) followed by autologous stem cell transplantation: CORAL study. *J Clin Oncol* 2009; 27: 15s
38. Blay J et al. The International Prognostic Index correlates to survival in patients with aggressive lymphoma in relapse: analysis of the PARMA trial. *Parma Group. Blood* 1998; 92(10): 3562–8
39. Wiernik PH et al. Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma. *J Clin Oncol* 2008; 26(30): 4952–7

40. Younes A et al. Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naive patients with CD20-positive B-cell non-Hodgkin lymphoma: a non-randomised, phase 1b study. *Lancet Oncol* 2014; 15(9): 1019–26
41. Wilson WH et al. Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma. *Nature Medicine* 2015; 21: 922
42. Palanca-Wessels MC et al. Safety and activity of the anti-CD79B antibody–drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a phase 1 study. *Lancet Oncol* 2015; 16(6): 704–15
43. Sehn LH et al. Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma. *J Clin Oncol* 2020; 38(2): 155–65
44. Robinson SP et al. Chemoresistant or aggressive lymphoma predicts for a poor outcome following reduced-intensity allogeneic progenitor cell transplantation: an analysis from the Lymphoma Working Party of the European Group for Blood and Bone Marrow Transplantation. *Blood* 2002; 100(13): 4310–6
45. Glass B et al. Rituximab after lymphoma-directed conditioning and allogeneic stem-cell transplantation for relapsed and refractory aggressive non-Hodgkin lymphoma (DSHNHL R3): an open-label, randomised, phase 2 trial. *Lancet Oncol* 2014; 15(7): 757–66
46. Schuster SJ et al. Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma. *N Engl J Med*. 2019; 380(1): 45–56
47. Neelapu SS et al. Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma. *N Engl J Med* 2017; 377(26): 2531–44
48. Pfreundschuh M et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. *Lancet Oncol* 2006; 7(5): 379–91
49. Chiappella A et al. Rituximab-dose-dense chemotherapy with or without high-dose chemotherapy plus autologous stem-cell transplantation in high-risk diffuse large B-cell lymphoma (DLCL04): final results of a multicentre, open-label, randomised, controlled, phase 3 study. *Lancet Oncol* 2017; 18(8): 1076–88
50. Bartlett NL et al. Dose-Adjusted EPOCH-R Compared With R-CHOP as Frontline Therapy for Diffuse Large B-Cell Lymphoma: Clinical Outcomes of the Phase III Intergroup Trial Alliance/CALGB 50303. *J Clin Oncol* 2019; 37(21): 1790–9
51. Duhresen U et al. Positron Emission Tomography-Guided Therapy of Aggressive Non-Hodgkin Lymphomas (PETAL): A Multicenter, Randomized Phase III Trial. *J Clin Oncol* 2018; 36(20): 2024–34
52. Vitolo U et al. Obinutuzumab or Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Previously Untreated Diffuse Large B-Cell Lymphoma. *J Clin Oncol* 2017; 35(31): 3529–37
53. Leonard JP et al. Randomized Phase II Study of R-CHOP With or Without Bortezomib in Previously Untreated Patients With Non-Germinal Center B-Cell-Like Diffuse Large B-Cell Lymphoma. *J Clin Oncol* 2017; 35(31): 3538–46
54. Witzig TE et al. Salvage chemotherapy with rituximab DHAP for relapsed non-Hodgkin lymphoma: a phase II trial in the North Central Cancer Treatment Group. *Leuk Lymphoma* 2008; 49(6): 1074–80
55. Kewalramani T et al. Rituximab and ICE as second-line therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphoma. *Blood* 2004; 103(10): 3684–8
56. El Gnaoui T et al. Rituximab, gemcitabine and oxaliplatin: an effective salvage regimen for patients with relapsed or refractory B-cell lymphoma not candidates for high-dose therapy. *Ann Oncol* 2007; 18(8): 1363–8
57. Gisselbrecht C et al. Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. *J Clin Oncol* 2010; 28(27): 4184–90
58. Crump M et al. Randomized comparison of gemcitabine, dexamethasone, and cisplatin versus dexamethasone, cytarabine, and cisplatin chemotherapy before autologous stem-cell

transplantation for relapsed and refractory aggressive lymphomas: NCIC-CTG LY.12. *J Clin Oncol* 2014; 32(31): 3490–6

59. van Imhoff GW et al. Ofatumumab Versus Rituximab Salvage Chemoimmunotherapy in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: The ORCHARRD Study. *J Clin Oncol* 2016: JCO2016690198

Periphere T-Zell-Lymphome (PTZL) (S. 38–43)

P. Reimer

1. Swerdlow H Campo E, Pileri SA et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. *Blood* 2016; 127: 2375–2390
2. Anonymous. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Classification Project. *Blood* 1997; 89: 3909–3918
3. Petrich AM, Helenowski IB, Bryan LJ et al. Factors predicting survival in peripheral T-cell lymphoma in the USA: a population-based analysis of 8802 patients in the modern era. *Br J Haematol* 2015; 168: 708–718
4. Vose J, Armitage J, Weisenburger D; International T-Cell Lymphoma Project. International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes. *J Clin Oncol* 2008; 26: 4124–4130
5. Nakamura S, Suchi T, Koshikawa T et al. Clinicopathologic study of 212 cases of peripheral T-cell lymphoma among the Japanese. *Cancer* 1993; 72: 1762–1772
6. Wang SS and Vose J. Epidemiology and Prognosis of T-Cell Lymphoma. In *T-Cell Lymphomas* Foss F eds. 2013 Springer ISBN: 978-1-62703-169-1
7. Greer JP, Kinney MC, Loughran TP, Jr. T cell and NK cell lymphoproliferative disorders. *Hematology (Am Soc Hematol Educ Program)* 2001: 259–281
8. Gisselbrecht C, Gaulard P, Lepage E et al. Prognostic significance of T-cell phenotype in aggressive non-Hodgkin's lymphomas. Groupe d'Etudes des Lymphomes de l'Adulte (GELA). *Blood* 1998; 92: 76–82
9. Schmitz N, Trümper L, Ziepert M et al. Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin Lymphoma Study Group. *Blood* 2010; 116: 3418–3425
10. Gallamini A, Stelitano C, Calvi R et al. Peripheral T-cell lymphoma unspecified (PTCL-U): a new prognostic model from a retrospective multicentric clinical study. *Blood* 2004; 103: 2474–2479
11. Federico M, Bellei M, Marcheselli L et al. Peripheral T cell lymphoma, not otherwise specified (PTCL-NOS). A new prognostic model developed by the International T cell Project Network. *Br J Haematol* 2018; 18: 760–769
12. Went P, Agostinelli C, Gallamini A et al. Marker expression in peripheral T-cell lymphoma: a proposed clinical-pathologic prognostic score. *J Clin Oncol* 2006; 24: 2472–2479
13. Gleeson M, Peckitt C, To YM et al. CHOP versus GEM-P in previously untreated patients with peripheral T-cell lymphoma (CHEMO-T): a phase 2, multicentre, randomised, open-label trial. *Lancet Haematol* 2018; 5:e190–e200
14. Savage, KJ Aggressive peripheral T-cell lymphomas (specified and unspecified types). *Hematology American Society of Hematology Education Program* 2005; 267–277
15. Ellin F, Landstrom J, Jerkeman M, Relander T. Real-world data on prognostic factors and treatment in peripheral T-cell lymphomas: a study from the Swedish Lymphoma Registry. *Blood* 2014; 124: 1570–1577
16. Pfreundschuh M, Trümper L, Kloess M et al.: Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL. *Blood* 2004; 104: 634–641

17. Corradini P, Tarella C, Zallio F et al. Long-term follow-up of patients with peripheral T-cell lymphomas treated up-front with high-dose chemotherapy followed by autologous stem cell transplantation. *Leukemia* 2006; 1533–1538
18. Rodríguez J, Conde E, Gutiérrez A et al. Frontline autologous stem cell transplantation in high-risk peripheral T-cell lymphoma: A prospective study from the Gel-Tamo Study Group. *Eur J Haematol* 2007; 79: 32–38
19. Mercadal S, Briones J, Xicoy B et al. Intensive chemotherapy (high-dose CHOP/ESHAP regimen) followed by autologous stem-cell transplantation in previously untreated patients with peripheral T-cell lymphoma. *Ann Oncol* 2008; 19: 958–963
20. Reimer P, Rüdiger T, Geissinger E et al. Autologous stem cell transplantation (autoSCT) as first-line therapy in peripheral T cell lymphomas (PTCL). Results of a prospective multicenter study. *J Clin Oncol* 2009; 27: 106–113
21. D'Amore F, Relander T, Lauritzsen G et al. Up-front autologous stem-cell transplantation in peripheral T-cell lymphoma: NLG-T-01. *J Clin Oncol* 2012; 30: 3093–3099
22. Fossard G, Broussais F, Coelho I et al. Role of up-front autologous stem-cell transplantation in peripheral T-cell lymphoma for patients in response after induction: an analysis of patients from LYSA centers. *Ann Oncol* 2018; 29: 715–723
23. Hopfinger G, Herling M, Krasniqi F et al. Periphäre T-Zell Lymphome Onkopedia-Leitline, aktualisiert 09/2019
24. Schmitz N, Nickelsen M, Altmann B et al. Allogeneic or autologous transplantation as first-line therapy for younger patients with peripheral T-cell lymphoma: Results of the interim analysis of the AATT trial. *J Clin Oncol* 2015; suppl; abstract #8507
25. Savage KJ, Harris NL, Vose JM et al. ALK- anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project. *Blood* 2008; 111: 5496–5504
26. Yang Y, Zhu Y, Cao JZ et al. Risk-adapted therapy for early-stage extranodal nasal-type NK/T-cell lymphoma: analysis from a multicenter study. *Blood* 2015; 126: 1424–1432
27. Yamaguchi M, Tobinai K, Oguchi M et al. Concurrent chemoradiotherapy for localized nasal natural killer/T-cell lymphoma: an updated analysis of the Japan clinical oncology group study JCOG0211. *J Clin Oncol* 2012; 30: 4044–4046
28. Yamaguchi M, Kwong YL, Kim WS et al. Phase II study of SMILE chemotherapy for newly diagnosed stage IV, relapsed, or refractory extranodal natural killer (NK)/T-cell lymphoma, nasal type: the NK-Cell Tumor Study Group study. *J Clin Oncol* 2011; 29: 4410–4416
29. Sieniawski M, Angamuthu N, Boyd K et al. Evaluation of enteropathy-associated T-cell lymphoma comparing standard therapies with a novel regimen including autologous stem cell transplantation. *Blood* 2010; 115: 3664–3670
30. Horwitz S, O'Connor OA, Pro B et al. ECHELON-2 Study Group. Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial. *Lancet* 2019; 393: 229–240
31. Mak V, Hamm J, Chhanabhai M et al. Survival of patients with peripheral T-cell lymphoma after first relapse or progression: spectrum of disease and rare long-term survivors. *J Clin Oncol* 2013; 31: 1970–1976
32. Doderer A, Spina F, Narni F et al. Allogeneic transplantation following a reduced-intensity conditioning regimen in relapsed/refractory peripheral T-cell lymphomas: long-term remissions and response to donor lymphocyte infusions support the role of a graft-versus-lymphoma effect. *Leukemia* 2012; 26: 520–526
33. Jacobsen ED, Kim HT, Ho VT et al. A large single-center experience with allogeneic stem-cell transplantation for peripheral T-cell non-Hodgkin lymphoma and advanced mycosis fungoides/Sezary syndrome. *Ann Oncol* 2011; 22: 1608–1613
34. Kanakry JA, Kasamon YL, Gocke CD et al. Outcomes of related donor HLA-identical or HLA-haploidentical allogeneic blood or marrow transplantation for peripheral T cell lymphoma. *Biol Blood Marrow Transplant* 2013; 19: 602–606

35. Kyriakou C, Canals C, Finke J et al. Allogeneic stem cell transplantation is able to induce long-term remissions in angioimmunoblastic T-cell lymphoma: a retrospective study from the lymphoma working party of the European group for blood and marrow transplantation. *J Clin Oncol* 2009; 27: 3951–3958
 36. Le Gouill S, Milpied N, Buzyn A et al. Graft-versus-lymphoma effect for aggressive T-cell lymphomas in adults: a study by the Societe Francaise de Greffe de Moelle et de Therapie Cellulaire. *J Clin Oncol* 2008; 26: 2264–2271
 37. Smith SM, Burns LJ, van Besien K et al. Hematopoietic cell transplantation for systemic mature T-cell non-Hodgkin lymphoma. *J Clin Oncol* 2013; 31: 3100–3109
 38. Corradini P, Doderio A, Zallio F et al. Graft-versus-lymphoma effect in relapsed peripheral T-cell non-Hodgkin's lymphomas after reduced-intensity conditioning followed by allogeneic transplantation for hematopoietic cells. *J Clin Oncol* 2004; 22: 2172–2176
 39. Pro B, Advani R, Brice P, Bartlett NL et al. Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study. *J Clin Oncol* 2012; 30: 2190–2196
-

UPDATE:

Ernährung und Sport bei Krebs – Was gibt es zu beachten? (S.51–58)

Y. Zopf, H. J. Hermann, M. F. Neurath, D. Reljic

1. Berger NA. Obesity and cancer pathogenesis. *Ann NY Acad Sci* 2014; 1311: 57–76
2. Brown JC et al. Cancer, physical activity, and exercise. *Compr Physiol* 2012; 2: 2775–2809
3. Key TJ et al. The effect of diet on risk of cancer. *Lancet* 2002; 360: 861–868
4. Fearon KC. Cancer cachexia: developing multimodal therapy for a multidimensional problem. *Eur J Cancer* 2008; 44: 1124–1132
5. Arends J et al. ESPEN guidelines on nutrition in cancer patients. *Clin Nutr* 2017; 36: 11–48
6. Cereda E et al. Nutritional counseling with or without systematic use of oral nutritional supplements in head and neck cancer patients undergoing radiotherapy. *Radiother Oncol* 2018; 126: 81–88
7. Calle MC, and Fernandez ML. Effects of resistance training on the inflammatory response. *Nutr Res Pract* 2010; 4: 259–269
8. Tomlinson D et al. Effect of exercise on cancer-related fatigue: a metaanalysis. *AmJ PhysMed Rehabil* 2014; 93: 675–686
9. George SM et al. Better postdiagnosis diet quality is associated with reduced risk of death among postmenopausal women with invasive breast cancer in the women's health initiative. *Cancer Epidemiol Biomarkers Prev* 2014; 23: 575–583
10. Hojman P et al. Molecular Mechanisms Linking Exercise to Cancer Prevention and Treatment. *Cell Metab* 2018; 27: 10–21
11. Arends J et al. DGEM Steering Committee. S3-Leitlinie Klinische Ernährung in der Onkologie, AWMF-Register-Nr. 073/006. *Aktuel Ernährungsmed* 2015; 40: e1–e74
12. Kondrup J et al. Nutritional risk screening (NRS 2002): a new method based on an analysis of controlled clinical trials. *Clin Nutr* 2003; 22: 321–336
13. Kyle U G et al. Bioelectrical impedance analysis-part II: utilization in clinical practice. *Clin Nutr* 2004; 23: 1430–1453
14. Ward LC. Segmental bioelectrical impedance analysis: an update. *Curr Opin Clin Nutr Metab Care* 2012; 15: 424–429
15. Bosy-Westphal A et al. What makes a BI A equation unique? Validity of eight-electrode multifrequency BIA to estimate body composition in a healthy adult population. *Eur J Clin Nutr* 2013; 67 (Suppl 1): S14–S21

16. Bony-Westphal A et al. Quantification of whole-body and segmental skeletal muscle mass using phase sensitive 8-electrode medical bioelectrical impedance devices. *Eur J Clin Nutr* 2017; 71: 1061–1067
17. Norman K et al. Hand grip strength: outcome predictor and marker of nutritional status. *Clin Nutr* 2011; 30: 135–142
18. Simmonds MJ. Physical function in patients with cancer: psychometric characteristics and clinical usefulness of a physical performance test battery. *J Pain Symptom Manage* 2002; 24: 404–414
19. Fearon KC. Cancer cachexia and fat muscle physiology. *N Engl J Med* 2011; 365: 565–567
20. Argilés JM et al. Non muscle Tissues Contribution to Cancer Cachexia. *Mediators Inflamm* 2015: 182872
21. Fearon K et al. Understanding the mechanisms and treatment options in cancer cachexia. *Nat Rev Clin Oncol* 2013; 10: 90–99
22. Winter A et al. Normal protein anabolic response to hyperaminoacidemia in insulin-resistant patients with lung cancer cachexia. *Clin Nutr* 2012; 31: 765–773
23. Leedo E et al. The Effect of a Home Delivery Meal Service of Energy- and Protein-Rich Meals on Quality of Life in Malnourished Outpatients Suffering from Lung Cancer: A Randomized Controlled Trial. *Nutr Cancer* 2017; 69: 444–453
24. Beeken RJ et al. „What about diet?“ A qualitative study of cancer survivors' views on diet and cancer and their sources of information. *Eur J Cancer Care (Engl)* 2016; 25: 774–783
25. MacDonald AJ et al. Habitual Myofibrillar Protein Synthesis Is Normal in Patients with Upper GI Cancer Cachexia. *Clin Cancer Res* 2015; 21: 1734–1740
26. Breen L, Phillips SM. Nutrient interaction for optimal protein anabolism in resistance exercise. *Curr Opin Clin Nutr Metab Care* 2012; 15: 226–232
27. Isenring EA et al. Nutrition intervention is beneficial in oncology outpatients receiving radiotherapy to the gastrointestinal or head and neck area. *Br J Cancer* 2004; 91: 447–452
28. Ravasco P et al. Impact of nutrition on outcome: a prospective randomized controlled trial in patients with head and neck cancer undergoing radiotherapy. *Head Neck* 2005; 27: 659–668
29. Wolin KY et al. Physical activity and colon cancer prevention: a metaanalysis. *Br J Cancer* 2009; 100: 611–616
30. Wu Y et al. Physical activity and risk of breast cancer: a metaanalysis of prospective studies. *Breast Cancer Res Treat* 2013; 137: 869–882
31. Olsen CM et al. Australian Ovarian Cancer Study Group. Recreational physical activity and epithelial ovarian cancer: a case-control study, systematic review, and meta-analysis. *Cancer Epidemiol Biomarkers Prev* 2007; 16: 2321–2330
32. Schmid D et al. A systematic review and meta-analysis of physical activity and endometrial cancer risk. *Eur J Epidemiol* 2015; 30: 397–412
33. Thune I et al. Physical activity and the risk of breast cancer. *N Engl J Med* 1997; 336: 1269–1275
34. Schmidt ME et al. Physical activity and postmenopausal breast cancer: effect modification by breast cancer subtypes and effective periods in life. *Cancer Epidemiol Biomarkers Prev* 2008; 17: 3402–3410
35. Moore SC et al. Association of Leisure-Time Physical Activity With Risk of 26 Types of Cancer in 1.44 Million Adults. *JAMA Intern Med* 2016; 176: 816–825
36. Smits A et al. The effect of lifestyle interventions on the quality of life of gynaecological cancer survivors: A systematic review and metaanalysis. *Gynecol Oncol* 2015; 139: 546–552
37. Holmes MD et al. Physical activity and survival after breast cancer diagnosis. *JAMA* 2005; 293: 2479–2486
38. Hayes SC et al. Exercise following breast cancer: exploratory survival analyses of two randomised, controlled trials. *Breast Cancer Res Treat* 2018; 167: 505–514
39. Fairman CM et al. Effects of exercise interventions during different treatments in breast cancer. *J Community Support Oncol* 2016; 14: 200–209
40. Mizrahi D et al. An Exercise Intervention During Chemotherapy for Women With Recurrent Ovarian Cancer: A Feasibility Study. *Int J Gynecol Cancer* 2015; 25: 985–992

41. Daher IN et al. The prevention of cardiovascular disease in cancer survivors. *Tex Heart Inst J* 2012; 39: 190–198
 42. Peel AB et al. Cardiorespiratory fitness in breast cancer patients: a call for normative values. *J Am Heart Assoc* 2014; 3: e000432
 43. Jones LW et al. Effect of exercise training on peak oxygen consumption in patients with cancer: a meta-analysis. *Oncologist* 2011; 16: 112–120
 44. Cormie P et al. The Impact of Exercise on Cancer Mortality, Recurrence, and Treatment-Related Adverse Effects. *Epidemiol Rev* 2017; 39: 71–92
 45. Padilha CS et al. Evaluation of resistance training to improve muscular strength and body composition in cancer patients undergoing neoadjuvant and adjuvant therapy: a meta-analysis. *J Cancer Surviv* 2017; 11: 339–349
 46. Hardee JP et al. The effect of resistance exercise on all-cause mortality in cancer survivors. *Mayo Clin Proc* 2014; 89: 1108–1115
 47. Mishra SI et al. Exercise interventions on healthrelated quality of life for cancer survivors. *Cochrane Database Syst Rev* 2012; 8: CD007566
 48. Van Blarigan EL, Meyerhardt JA. Role of physical activity and diet after colorectal cancer diagnosis. *J Clin Oncol* 2015; 33: 1825–1834
 49. Dos Santos WDN et al. Chronic Effects of Resistance Training in Breast Cancer Survivors. *Biomed Res Int* 2017; 2017: 8367803
 50. Albrecht TA et al. A complementary care study combining flaxseed oil, caffeine, fasting, and exercise in women diagnosed with advanced ovarian cancer: findings from a case study. *Holist Nurs Pract* 2012. 26: 308–316
 51. Oldervoll LM et al. Physical exercise for cancer patients with advanced disease: a randomized controlled trial. *Oncologist* 2011; 16: 1649–1657
 52. Stene GB et al. Effect of physical exercise on muscle mass and strength in cancer patients during treatment – a systematic review. *Crit Rev Oncol Hematol* 2013; 88: 573–593
 53. Heywood R, McCarthy AL, Skinner TL. Safety and feasibility of exercise interventions in patients with advanced cancer: a systematic review. *Support Care Cancer* 2017; 25: 3031–3050
 54. Schink K et al. Effects of whole-body electromyostimulation combined with individualized nutritional support on body composition in patients with advanced cancer: a controlled pilot trial. *BMC Cancer* 2018; 18: 886
 55. Schink K et al. Whole-Body Electromyostimulation Combined With Individualized Nutritional Support Improves Body Composition in Patients With Hematological Malignancies – A Pilot Study. *Front Physiol* 2018; 9: 1808
 56. Carpenter CL et al. Effect of family history, obesity and exercise on breast cancer risk among postmenopausal women. *Int J Cancer* 2003; 106: 96–102
 57. Bruno E et al. Effect of aerobic exercise intervention on markers of insulin resistance in breast cancer women. *Eur J Cancer Care (Engl)* 2018; 27: e12617
 58. Barnes BB et al. Cancer risk factors associated with insulin-like growth factor (IGF)-I and IGF-binding protein-3 levels in healthy women: effect modification by menopausal status. *Cancer Causes Control* 2009; 20: 1985–1996
 59. Schmidt S et al. The integrative role of leptin, oestrogen and the insulin family in obesity-associated breast cancer: potential effects of exercise. *Obes Rev* 2015; 16: 473–487
-